Short answer
PepGen Inc (PEPG) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $125.0 million common-stock offering: 25.0 million shares at $5.00 each.
PepGen Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $125.0 million common-stock offering: 25.0 million shares at $5.00 each
- Underwriters’ 30-day option for 3.75 million additional shares, potentially increasing gross proceeds by $18.75 million
- Estimated net proceeds $116.9 million, or $134.5 million with full option exercise
- Funding directed to ongoing clinical development, working capital and general corporate purposes
- Expected November 13, 2026 closing, subject to customary conditions; substantial share issuance creates dilution risk for existing holders
Item 8.01 · Other Events
- PepGen launched a securities offering on November 10, 2026
- Offering pricing announced November 11, 2026
- Investors should review Exhibits 99.1 and 99.2 for security type, proceeds, dilution and offering terms
Item EX-99.1 · Exhibit EX-99.1
- Proposed $125.0 million common-stock offering, primarily funding clinical development and corporate needs
- Underwriters’ 30-day option could add $18.75 million, increasing potential proceeds
- Equity financing implies shareholder dilution, with final size and terms still subject to market conditions
- Pre-funded warrants offered to certain investors as an alternative to common stock
- Proceeds expected to support PGN-EDODM1 development for myotonic dystrophy type 1
Item EX-99.2 · Exhibit EX-99.2
- $125 million gross equity offering: 25,000,000 shares priced at $5.00 each
- Potential additional dilution: underwriters hold a 30-day option for 3,750,000 shares
- Proceeds earmarked for ongoing clinical development, working capital and general corporate purposes
- Expected closing November 13, 2026, subject to customary conditions
- Capital supports PGN-EDODM1 development while increasing shares outstanding and dilution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PepGen Inc 8-K filings
Get the next PEPG 8-K as it lands
Follow PEPG for push alerts, or ask the research agent what this filing means.